Research report on sandoz biosimilars company analysis
Upcoming SlideShare
Loading in...5
×
 

Research report on sandoz biosimilars company analysis

on

  • 1,151 views

Sandoz is the only company with three marketed biosimilars in Europe, each of which is now the leading biosimilar in its respective market segment. The firm also has a wide variety of biosimilars in ...

Sandoz is the only company with three marketed biosimilars in Europe, each of which is now the leading biosimilar in its respective market segment. The firm also has a wide variety of biosimilars in its portfolio including nine biosimilars in development.

Statistics

Views

Total Views
1,151
Views on SlideShare
1,151
Embed Views
0

Actions

Likes
0
Downloads
13
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Research report on sandoz biosimilars company analysis Research report on sandoz biosimilars company analysis Document Transcript

  • Research Report on Sandoz: Biosimilars Company Analysis This analysis evaluates the company’s strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company’s biosimilars portfolio, including analysis of key product profiles, examining key drivers and resistors to development, market sizing, specifics of development such as clinical trials (where available) for each key biosimilar molecule in development. Features and benefits Strategic insight into the key strategies that have shaped the companys progress and/or will define its outlook going forward. Provides an indication of how biosimilars fit into the wider company context, and a history of deals & alliances. Highlights Sandoz is the only company with three marketed biosimilars in Europe, each of which is now the leading biosimilar in its respective market segment. The firm also has a wide variety of biosimilars in its portfolio including nine biosimilars in development. Your key questions answered See how Sandoz became the first generics company to gain approval for a biosimilar product Evaluate the firms wide variety of biosimilars in its portfolio, including nine biosimilars in development Buy Your Copy of Report: http://www.reportsnreports.com/reports/175349-sandoz-biosimilars- company-analysis.html Published: July 2012 No. of Pages: 37 Price Single User License: US $ 3800 Price Corporate User License: US $ 9500
  • Table Of ContentsABOUT THIS REPORTCHAPTER STRUCTUREExecutive summaryStrategic insightProduct analysisOperating performanceCompany introductionDATA SOURCINGSales dataAnalyst consensusPharmaVitae explorer databaseEXECUTIVE SUMMARYSandoz biosimilars overviewSandoz biosimilars infrastructureSTRATEGIC INSIGHTSandoz biosimilars SWOT analysisStrengthsWeaknessesOpportunitiesThreatsSandoz has focused on producing difficult-to-make biosimilars with the greatest sales potentialAggressive M&A strategy has given Sandoz a strong market positionHowever, its biosimilar portfolio is difficult to valueKEY PRODUCTSOverviewSandoz biosimilar portfolioOmnitropeOverviewSomatropin market sizingKey competitorsSandoz biosimilar developmentClinical trialsBinocritOverviewErythropoietin market sizingKey competitorsSandoz biosimilar developmentClinical trials
  • ZarzioOverviewFilgrastim market sizingKey competitorsSandoz biosimilar developmentClinical trialsGP2013OverviewRituximab market sizingKey competitorsSandoz biosimilar developmentClinical trialsOPERATING PERFORMANCEOperating costs and profit analysisOperating costs and profit analysis, 2004–16Operating cost ratio and profit margin analysis, 2004–16CORPORATE STRUCTUREKey findingsCORPORATE RELATIONSHIPSRecent developmentsAPPENDIXREFERENCESEXCHANGE RATESList Of TablesTable: Sandoz – manufacturing and development metricsTable: Sandoz – biosimilar portfolioTable: Forecast somatropin sales ($m), 2011–16Table: Biosimilar somatropin drugs, 2012Table: Sandoz biosimilar Omnitrope clinical trialsTable: Forecast epoetin and darbepoetin sales ($m), 2011–16Table: Biosimilar epoetin drugs, 2012Table: Sandoz biosimilar erythropoietin clinical trialsTable: Forecast filgrastim and pegfilgrastim sales ($m), 2011–16Table: Biosimilar filgrastim drugs, 2012Table: Biosimilar pegfilgrastim drugs, 2012Table: Sandoz biosimilar filgrastim clinical trialsTable: Forecast MabThera sales ($m), 2011–16
  • Table: Biosimilar rituximab drugs, 2012Table: Sandoz biosimilar GP2013 clinical trialsTable: Sandoz operating revenues, costs, and profit ($m), 2004–10Table: Sandoz operating revenues, costs, and profit ($m), 2010–16Table: Sandoz operating cost ratios and profit margin (as a percentage of total revenues), 2004–10Table: Sandoz operating cost ratios and profit margin (as a percentage of total revenues), 2010–16Table: Sandoz – deal activity and biosimilar dealsTable: Exchange rates, 2011List Of FiguresFigure: The PharmaVitae ExplorerFigure: Sandoz biosimilars overviewFigure: Sandoz operating revenues, costs, and profit ($m), 2004–16Figure: Sandoz – revenue by geographic region, 2011Figure: Sandoz – revenue by segment, 2011Browse more Research Reports @ http://www.reportsnreports.com/market-research/company-profiles/Contact Us:TX, Dallas North - Dominion Plaza,17304, Preston Road,Suite 800, Dallas 75252.+ 1 888 391 5441Email: sales@reportsandreports.comConnect With Us: